Clinica e Investigacion en Arteriosclerosis
metrics 2024
Fostering collaboration in cardiology and pharmacology advancements.
Introduction
Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
VASCULAR PHARMACOLOGY
Elevating the standards of vascular pharmacological research.Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.
International Cardiovascular Research Journal
Connecting global experts in cardiovascular research.International Cardiovascular Research Journal, published by Shiraz University Medical Sciences, serves as a vital platform for the dissemination of cutting-edge research in the field of cardiology and cardiovascular medicine. Since its inception in 2011, this journal has continuously devoted itself to promoting the highest quality of scholarly communication, helping to bridge the gap between laboratory findings and clinical application. With an ISSN of 2251-9130 and an E-ISSN of 2251-9149, it is indexed in prominent databases, contributing to its visibility and accessibility to a global audience. Although currently classified in the Q4 quartile in the 2023 rankings, the journal is committed to enhancing its impact factor and academic stature. It aims to facilitate open access for all published articles, although specific details on access options are pending. Through its rigorous peer-review process and diverse scope—which encapsulates advancements, clinical studies, and innovative therapeutic strategies—this journal fosters academic collaboration in the realm of cardiovascular health, making it an invaluable resource for researchers, practitioners, and students alike.
HEART
Leading the Charge in Cardiovascular MedicineHEART is a leading peer-reviewed journal published by the BMJ Publishing Group, specializing in the field of Cardiology and Cardiovascular Medicine. Established in 1942, the journal has evolved as a premier platform for disseminating high-quality research, innovative practices, and clinical advancements within the cardiovascular domain. With an impressive impact factor and ranked in the Q1 category in 2023, it positions itself among the top-tier journals in its field, boasting a Scopus rank of #37 out of 387 in this highly competitive area, representing the top 10th percentile nationally. The journal supports both traditional and open access options, thereby enhancing the global visibility and reach of its published work. Researchers, professionals, and students alike will find HEART to be an invaluable resource, offering the latest insights and developments that drive the field forward and improve patient care worldwide.
Journal of the Practice of Cardiovascular Sciences
Innovating Solutions in Cardiovascular HealthJournal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.
Current Atherosclerosis Reports
Unveiling the latest in atherosclerosis research.Current Atherosclerosis Reports, published by CURRENT MEDICINE GROUP, is a leading scientific journal in the field of Cardiology and Cardiovascular Medicine, boasting an impressive Q1 ranking in its category as of 2023. This esteemed journal, with an ISSN of 1523-3804 and an E-ISSN of 1534-6242, has been a cornerstone of cardiovascular research since its inception in 1999, continuing to publish cutting-edge studies through 2024. With unparalleled insights into the mechanisms, prevention, and treatment of atherosclerosis, it serves as an essential resource for researchers, healthcare professionals, and students alike. Although not an open-access journal, it is highly regarded within the academic community, highlighted by its Scopus rank of #54 out of 387 in its field, placing it in the 86th percentile. The journal's commitment to advancing knowledge in cardiovascular health underscores its integral role in guiding clinical practices and influencing future research directions.
Cardiology and Therapy
Exploring breakthroughs in heart health and therapy.Cardiology and Therapy, published by SPRINGER LONDON LTD, is a leading open-access journal dedicated to advancing the field of cardiology and cardiovascular medicine. With an ISSN of 2193-8261 and an E-ISSN of 2193-6544, this esteemed journal has been at the forefront of disseminating high-quality research since its inception in 2012. It has achieved an impressive Q1 ranking in the 2023 Cardiology and Cardiovascular Medicine category, reflecting its commitment to excellence and relevance in the field. Spanning a wide array of topics—from clinical studies to cutting-edge therapeutic interventions—the journal aims to foster knowledge exchange among researchers, clinicians, and healthcare professionals. In addition, its position in the 72nd percentile of Scopus rankings underscores its global impact and contribution to the cardiovascular research community. With open access options, Cardiology and Therapy ensures that its content is widely accessible, promoting the sharing of vital findings that can influence clinical practice and improve patient outcomes.
CIRCULATION
Leading the Charge in Heart Health Research.CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.
Netherlands Heart Journal
Exploring Innovations in Heart Health and Disease ManagementNetherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.
Cardiovascular Therapeutics
Empowering Global Access to Cardiovascular DiscoveriesCardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.
International Journal of Cardiology Cardiovascular Risk and Prevention
Fostering Global Collaboration in Cardiovascular ResearchInternational Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.